Vertex Pharmaceuticals (NASDAQ:VRTX) has been given a buy rating by UBS, who believes that the company has significant growth potential.

UBS predicts that Vertex will achieve a compound annual growth rate (CAGR) of around 11% from 2023 to 2028, surpassing the estimated 5% growth rate of its large-cap peers. This indicates confidence in the company's ability to capitalize on market opportunities and sustain growth in the future.

UBS also states that Vertex is expected to outperform its sector in terms of both revenue and profitability. This further highlights the belief in the company's potential to outshine its competitors and achieve success in the market.